Why can’t investors think for themselves? How do parents cope with inexplicable tragedy? And is tech prepared for the toughest parts of health care?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, we dig into the potential merger of Bristol-Myers Squibb and Celgene, explaining the obscure but powerful firms that could sway whether shareholders approve the deal. Then, STAT’s Eric Boodman joins us to talk about his story on the emotional toll, scientific suspense, and bureaucratic frustration that confronts parents whose infants unexpectedly die. Then we delve into an unforeseen challenge that many digital health startups are facing: What to do when patients use their platforms to express that they’re feeling suicidal?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy